National Cancer Institute (NCI): Carcinoma, Renal Cell trials

The registry lists 118 Carcinoma, Renal Cell studies with National Cancer Institute (NCI) as lead sponsor. 9 are open to participants now and 50 have results posted.

Phase 1 43Phase 2 76Phase 3 7No phase 6(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07689240Phase 3
• Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingNCT07516366Phase 2
• Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingNCT05665361Phase 1/2
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaRecruitingNCT05155033Phase 2
• Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingNCT04981509Phase 2
• A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesRecruitingNCT04923178
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruitingNCT00001238
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal CarcinomaTerminatedNCT04150562Phase 2Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyActive, not recruitingNCT03055013Phase 3Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal CancerTerminatedNCT02504892Phase 2Results posted
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaTerminatedNCT02495103Phase 1/2Results posted
• Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney CancersCompletedNCT02141490Phase 2Results posted
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompletedNCT02019693Phase 2Results posted
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedNCT01835158Phase 2Results posted
• Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney CancerCompletedNCT01727089Phase 2Results posted
• Imaging Studies of Kidney Cancer Using 18F-VM4-037TerminatedNCT01712685Phase 2Results posted
• Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryCompletedNCT01688973Phase 2Results posted
• Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney CancerCompletedNCT01664182Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryActive, not recruitingNCT01575548Phase 3Results posted
• Vandetanib to Treat Advanced Kidney CancerTerminatedNCT01372813Phase 2Results posted
• Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerTerminatedNCT01239342Phase 2Results posted
• Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line TherapyTerminatedNCT01198158Phase 3Results posted
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal CancerTerminatedNCT01160445Phase 2Results posted
• A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) TherapyCompletedNCT01141569Phase 2Results posted
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerCompletedNCT01130519Phase 2Results posted
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney CancerActive, not recruitingNCT01038778Phase 1/2Results posted
• Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum ToxinCompletedNCT00971620Phase 2Results posted
• Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney CancerCompletedNCT00923845Phase 2Results posted
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...CompletedNCT00923481Phase 2Results posted
• Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney CancerCompletedNCT00923130Phase 2Results posted
• Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney CancerTerminatedNCT00684996Phase 1/2Results posted
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerTerminatedNCT00670748Phase 2Results posted
• Phase II Study of Vandetanib in Individuals With Kidney CancerCompletedNCT00566995Phase 2Results posted
• Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney CancerCompletedNCT00408902Phase 2Results posted
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney CancerCompletedNCT00378703Phase 2Results posted
• Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00357760Phase 2Results posted
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By SurgeryCompletedNCT00326898Phase 3Results posted
• Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00324870Phase 1/2Results posted
• Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney CancerTerminatedNCT00324740Phase 1/2Results posted
• AZD2171 in Treating Patients With Refractory Metastatic Kidney CancerTerminatedNCT00303862Phase 2Results posted
• Vorinostat in Treating Patients With Kidney CancerCompletedNCT00278395Phase 2Results posted
• Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00227760Phase 2Results posted
• Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney CancerTerminatedNCT00126659Phase 2Results posted
• Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerCompletedNCT00126594Phase 2Results posted
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney CancerCompletedNCT00126503Phase 1/2Results posted
• Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00126490Phase 2Results posted
• Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney CancerCompletedNCT00121251Phase 1/2Results posted
• CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00112840Phase 1/2Results posted
• Vaccine Treatment of Kidney CancerTerminatedNCT00089778Phase 2Results posted
• 17AAG to Treat Kidney Tumors in Von Hippel-Lindau DiseaseCompletedNCT00088374Phase 2Results posted
• BMS 247550 to Treat Kidney CancerCompletedNCT00030992Phase 2Results posted
• Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell CarcinomaTerminatedNCT00001703Phase 2Results posted
• Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialActive, not recruitingNCT05411081Phase 2
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingNCT04235777Phase 1
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL StudyActive, not recruitingNCT04071223Phase 2
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2Active, not recruitingNCT03284385Phase 2
• Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryTerminatedNCT02595918Phase 1
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingNCT01480154Phase 1
• Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid MalignanciesCompletedNCT01243359Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid TumorsCompletedNCT01198184Phase 1
• A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid TumorsWithdrawnNCT01176500Phase 1/2
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell CancerCompletedNCT01021059Phase 1
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00937482Phase 1
• A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced MalignanciesCompletedNCT00923520Phase 1
• Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 ReceptorTerminatedNCT00923390Phase 1
• Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)CompletedNCT00923169Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Follow-Up Study of Kidney Cancer PatientsCompletedNCT00656955
• Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid TumorsCompletedNCT00499135Phase 1
• Ispinesib in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00354250Phase 2
• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00348699Phase 1
• Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United StatesCompletedNCT00340457
• Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerCompletedNCT00304460Phase 1
• Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the BrainCompletedNCT00301847Phase 2
• Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00217542Phase 1
• Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney CancerCompletedNCT00182702Phase 2
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00112476Phase 1
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00101114Phase 2
• Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNCT00098618Phase 2
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) CancerCompletedNCT00083109Phase 1/2